A research study to evaluate the efficacy of LEO 32731 oral tablet formulation in patients with moderate to severe psoriasis vulgaris.

Registry ID

EUCTR2015-005279-25

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

LEO Pharma A/S

Start date

2016-06-22

Completion date

2017-07-06

Last update

2026-08-16

Conditions

• Psoriasis Vulgaris

Summary

To investigate the efficacy of LEO 32731 30 mg as compared to placebo after 16 weeks of oral treatment of psoriasis vulgaris.

Locations

• , , Germany

Related clinical trials

• Shuiniujiao Dihuang Decoction With Variation for the Treatment of Psoriasis
• Psoriatic Immune Response to Tildrakizumab
• Correction of Psoriatic T Cell Signatures by Deucravacitinib
• Proactive TDM Versus Standard Use of Biologics in Psoriasis
• Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)
• Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris

View on source registry